Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.
J Immunother CancerSep 23, 2026 (epub)
Clinical ResearchOncology (Medical)
Jie-Tao Ma, Li Sun, Ling-Yun Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II trial evaluated ivonescimab combined with chemotherapy in seven patients with advanced thymic carcinoma. The study found a promising objective response rate (ORR) of 85.7% and a disease control rate (DCR) of 100% after a median follow-up of 6.4 months. The treatment was well-tolerated, with manageable safety profiles.
Key findings
- The objective response rate (ORR) was 85.7% (6/7; 95% CI 42.1% to 99.6%).
- The disease control rate (DCR) was 100%.
- Both 6-month progression-free survival (PFS) and overall survival (OS) rates were 100%.
- Grade ≥3 treatment-related adverse events occurred in 57.1% of patients.
Why it matters
The findings suggest that ivonescimab combined with chemotherapy may offer a new treatment option for advanced thymic carcinoma, a condition with limited effective therapies. The high response rates indicate potential for improved patient outcomes.